Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Article in Portuguese | LILACS, ColecionaSUS, CONASS, SES-GO | ID: biblio-1151190

ABSTRACT

Tecnologia: Teriparatida, comparada a bifosfonados orais ou Raloxifeno. Indicação: prevenção de fraturas em pessoas com osteoporose. Pergunta: A Teriparatida é mais eficaz e segura que os bifosfonados orais ou o Raloxifeno para tratamento da osteoporose e prevenção de fraturas secundárias à osteoporose? Métodos: Levantamento bibliográfico foi realizado na base de dados PUBMED, seguindo estratégias de buscas predefinidas. Foi feita avaliação da qualidade metodológica das revisões sistemáticas com a ferramenta Assessing the Methodological Quality of Systematic Reviews version 2 (AMSTAR-2). Resultados: Foram selecionadas 2 revisões sistemáticas, que atendiam aos critérios de inclusão. Conclusão: Para a população em geral com osteoporose, a Teriparatida evita mais fraturas vertebrais que o Alendronato de sódio ou Risedronato de sódio, mas efeito similar para fraturas não vertebrais. Teriparatida previne mais fraturas vertebrais e não vertebrais que Raloxifeno. Teriparatida tem maior efeito sobre a massa óssea corporal que o Risedronato de sódio e o Raloxifeno, mas tem efeito similar ao Alendronato de sódio. Na população masculina com osteoporose, a terapia com bifosfonados orais é mais eficaz que suplementação nutricional ou placebo para prevenir fraturas. Já o tratamento com Teriparatida não é mais eficaz que a suplementação nutricional ou placebo


Teriparatide compared to oral bisphosphonates or Raloxifene. Indication: prevention of fractures in people with osteoporosis. Question: Is Teriparatide more effective and safer than oral bisphosphonates or Raloxifene for treating osteoporosis and preventing fractures secondary to osteoporosis? Methods: Bibliographic survey was carried out in the PUBMED database, following predefined search strategies. Evaluation of the methodological quality of systematic reviews was carried out using the tool Assessing the Methodological Quality of Systematic Reviews version 2 (AMSTAR-2). Results: Two systematic reviews were selected, which met the inclusion criteria. Conclusion: For the general population with osteoporosis, Teriparatide prevents more vertebral fractures than Alendronate or Risedronate sodium, but has similar effect for non-vertebral fractures. Teriparatide prevents more vertebral and non-vertebral fractures than Raloxifene. Teriparatide has a greater effect on body bone mass than Risedronate sodium and Raloxifene, but it has a similar effect to Alendronate sodium. In the male population with osteoporosis, oral bisphosphonates is more effective than nutritional supplementation or placebo to prevent fractures. Treatment with teriparatide is no more effective than nutritional supplementation or placebo


Subject(s)
Humans , Teriparatide/therapeutic use , Raloxifene Hydrochloride/therapeutic use , Diphosphonates/therapeutic use , Osteoporotic Fractures/drug therapy , Efficacy , Spinal Fractures/drug therapy , Alendronate/therapeutic use , Evidence-Based Medicine , Risedronic Acid/therapeutic use , Denosumab/therapeutic use , Hip Fractures/drug therapy
2.
Article in Portuguese | LILACS, ColecionaSUS, CONASS, SES-GO | ID: biblio-1118551

ABSTRACT

Tecnologia: Denosumabe e bifosfonados. Indicação: tratamento de osteoporose para prevenção de fraturas. Pergunta: O denosumabe é mais eficaz e seguro que os bifosfonados orais para tratamento da osteoporose e prevenção de fraturas secundárias à osteoporose? Métodos: Levantamento bibliográfico realizado na PUBMED seguindo estratégia de busca predefinida. Avaliação da qualidade metodológica das revisões sistemáticas com a ferramenta AMSTAR (Assessing the Methodological Quality of Systematic Reviews). Resultados: Foram selecionadas e incluídas 3 revisões sistemáticas, com pontuação de 9 a 11 no AMSTAR. Conclusão: Denosumabe tem menor risco relativo que alendronato e risedronato de sódio para fraturas vertebrais e maior efeito sobre densidade óssea mineral femoral, com risco similar de outros tipos de fratura e eventos adversos (infecções, transtornos cardiovasculares, óbito por infecção, morte cardiovascular ou por qualquer causa). Denosumabe evita 0,00154 fraturas, previne 0,00025 institucionalizações (ou cuidados permanentes de enfermagem no domicílio) e promove um ganho de 0,0018 anos de vida a mais que o alendronato de sódio por paciente tratado. Denosumabe é um pouco mais eficaz e tão seguro quanto os bifosfonados, mas a diferença de eficácia é mínima


Technology: Denosumab and bisphosphonates. Indication: osteoporosis treatment for fracture prevention. Question: Denosumab is more effective and safer than oral bisphosphonates for treating osteoporosis and preventing fractures related to osteoporosis? Methods: Bibliographic search was performed on PUBMED, following predefined search strategies. Evaluation of the methodological quality of systematic reviews was carried out using the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) tool. Results: We selected and included 3 systematic reviews. Their scores ranged from 9 to 11 on AMSTAR. Conclusion: Denosumab has a lower relative risk than sodium alendronate and risedronate for vertebral fractures and greater effect on femoral mineral bone density, with a similar risk for non-vertebral fractures and adverse events (infections, cardiovascular disorders, death caused by infection, cardiovascular death or any cause mortality). Denosumab avoids 0.00154 fractures, prevents 0.00025 nursing home/ residential care admissions and get 0.0018 years of life gained per treated patient more than sodium alendronate. Denosumab is slightly more effective and as safe as bisphosphonates, but the effectiveness difference is minimal


Subject(s)
Humans , Osteoporosis/drug therapy , Alendronate/therapeutic use , Bone Density Conservation Agents/therapeutic use , Osteoporotic Fractures/prevention & control , Risedronic Acid/therapeutic use , Denosumab/therapeutic use , Treatment Outcome , Alendronate/adverse effects , Evidence-Based Medicine , Risedronic Acid/adverse effects , Denosumab/adverse effects
3.
Actual. osteol ; 15(2): 94-102, mayo - ago. 2019. tab.
Article in Spanish | LILACS | ID: biblio-1048478

ABSTRACT

El propósito de la terapia en el desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica (IRC) consiste en restaurar el balance mineral, y, en la osteoporosis, mantener o aumentar la masa ósea. Ambas terapias tratan de evitar la fractura ósea. La mayoría de los osteoactivos están contraindicados en la insuficiencia renal crónica avanzada (estadios 4 y 5), y las terapias son empíricas. Algunos autores opinan que sin anomalías bioquímicas del desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica avanzada se podría intentar el tratamiento estándar para la osteoporosis. Antes de intentar la terapia osteoactiva se debe corregir el desorden mineral óseo que pudiera presentarse asociado a la IRC, y en la indicación del tipo de osteoactivo se sugiere seleccionar al paciente según su estado óseo. Se aconseja que la administración de los antirresortivos se realice a dosis menores con respecto a los que tienen mejor función renal junto con aportes adecuados de calcio y vitamina D, antes y durante el tratamiento para prevenir el riesgo de severas hipocalcemias y un efecto óseo excesivo. Se presenta el caso clínico de una mujer de 65 años, con diagnóstico de osteoporosis de etiología multifactorial, fractura de pelvis, múltiples fracturas vertebrales e insuficiencia renal crónica avanzada, entre otras comorbilidades, y probable enfermedad ósea adinámica. Recibió inicialmente terapia con teriparatide y luego con denosumab, complicándose con hipocalcemia asintomática. (AU)


The purpose of therapy for the bone mineral metabolism disorder associated with chronic kidney disease is to restore the mineral balance; and to maintain or increase bone mass in osteoporosis. The goal of both types of therapy is to avoid bone fractures. Most antiosteoporotic drugs are contraindicated in advanced chronic renal failure (CRF) stages 4 and 5, and the therapies are empirical. Some authors believe that without biochemical abnormalities of the mineral bone metabolism disorder associated with advanced chronic kidney disease, standard treatment for osteoporosis could be attempted. Before attempting antiosteoporotic therapy, the bone mineral disorder that may be associated with CRF must be corrected, and in the indication of the type drug it is suggested that the patient be selected according to their bone status. It is advised that the administration of anti-resorptives be performed at lower doses in individuals with poor renal function compared to those with better renal function together with adequate calcium and vitamin D, before and during treatment to prevent the risk of severe hypocalcemia, and an excessive bone effect. We present the clinical case of a 65-year-old woman with a diagnosis of osteoporosis of multifactorial etiology, pelvic fracture, multiple vertebral fractures and advanced chronic renal failure, among other comorbidities and probable adynamic bone disease. The patient received initial therapy with teriparatide and followed by denosumab administration and exhibited asymptomatic hypocalcemia. (AU)


Subject(s)
Humans , Female , Aged , Chronic Kidney Disease-Mineral and Bone Disorder/drug therapy , Fractures, Bone/prevention & control , Osteoporosis/therapy , Chronic Kidney Disease-Mineral and Bone Disorder/complications , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/therapy , Vitamin D/administration & dosage , Vitamin D/therapeutic use , Calcium/administration & dosage , Calcium/therapeutic use , Alendronate/therapeutic use , Teriparatide/administration & dosage , Teriparatide/adverse effects , Teriparatide/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , Cinacalcet/therapeutic use , Risedronic Acid/therapeutic use , Denosumab/administration & dosage , Denosumab/adverse effects , Denosumab/therapeutic use , Hypocalcemia/prevention & control
5.
Rio de Janeiro; s.n; 2019. 66 p.
Thesis in Portuguese | LILACS, ColecionaSUS | ID: biblio-1177111

ABSTRACT

A osteoporose é um distúrbio osteometabólico caracterizado pela redução da densidade mineral óssea. Estima-se que 200 milhões de pessoas possuam osteoporose no mundo. A doença é fator de risco para falha do processo de fusão vertebral, que consiste na consolidação de vértebras adjacentes através da colocação de enxertia óssea e estabilização mecânica, fundamental para o sucesso das cirurgias da coluna vertebral. O alendronato é um medicamento antirreabsortivo utilizado no tratamento da osteoporose. Apesar de sua eficácia, sugere-se que retarda o processo de remodelamento no sítio cirúrgico da fusão vertebral, atrasando a osteointegração do enxerto aos corpos vertebrais. Ainda não há consenso sobre a melhor abordagem medicamentosa para os pacientes osteoporóticos que se encontram em uso crônico de alendronato e que serão submetidos ao procedimento cirúrgico de fusão vertebral. Este estudo avaliou o efeito do alendronato na consolidação óssea do procedimento de fusão vertebral em ratas osteoporóticas. Quinze ratas da linhagem Sprague Dawley foram divididas em três grupos: Grupo Não-OVX (n=3) - ratas não submetidas a ooforectomia e submetidas a fusão espinhal; Grupo OVX (n=5) - ratas submetidas a ooforectomia entre 8 a 12 semanas de vida e à fusão vertebral 12 semanas após a ooforectomia e Grupo ALN (n=7) - ratas ooforectomizadas e submetidas a fusão vertebral que receberam semanalmente 70µg/kg de alendronato iniciado 5 semanas antes da fusão vertebral e mantido até a eutanásia. Foram coletadas amostras de sangue semanalmente e os animais foram submetidos a eutanásia 8 semanas após a fusão vertebral. A condição osteoporótica foi confirmada através da dosagem por ELISA dos níveis plasmáticos de CTX-I 12 semanas após ooforectomia, que foi maior no grupo OVX em relação ao grupo Não-OVX (p=0,0086). Os parâmetros da microestrutura do corpo vertebral medidos através da microtomografia computadorizada (µCT) denotam redução na fração de volume ósseo (BV/TV) (p=0,116), no número de trabéculas (Tb.N) (p=0,116), na espessura das trabéculas (Tb.Th) (p=0,033), e leve aumento na desconexão entre as trabéculas (Tb.pf p = 0,086). Quanto à eficiência da fusão, a avaliação radiográfica do segmento lombar revelou taxa de fusão de 75% (3/4) no grupo Não-OVX, 100% (3/3) no grupo OVX e nenhuma fusão no grupo ALN. Pela avaliação manual, os resultados foram semelhantes para os grupos Não-OVX e OVX e de 57,1% (4/7) no grupo ALN. A avaliação dos aspectos estruturais da massa da fusão por µCT revelou maior BV/TV (p ≤ 0,05), maior Tb.N (p ≤ 0,01), maior espaçamento entre as trabéculas (Tb.Sp) (p ≤ 0,01) e Conn.Den (p = 0,02) no grupo ALN em relação aos grupos OVX e não OVX. O grupo ALN também apresentou maior Tb.Th (p = 0,04) e menor Tb.pf (p = 0,03) do que o grupo OVX. As ratas osteoporóticas submetidas a cirurgia de fusão vertebral e tratadas com alendronato apresentaram menor taxa de fusão vertebral, apesar de possuir melhor qualidade da massa de fusão. Imaginavamos que o tratamento crônico com alendronato, assim como o tratamento iniciado após a cirurgia, leve à formação de massas de fusão com maior qualidade trabecular e mais exuberantes, porém, diferente do observado quando o tratamento é iniciado após a cirurgia, não resulta em aumento na taxa de fusão


Osteoporosis is an osteometabolic disorder characterized by reduced bone mineral density. About 200 million people are affected in the world and the disease is a risk factor for pseudoarthrosis in spinal fusion. Alendronate is a bisphosphonate medication that inhibits bone resorption and is used to treat osteoporosis. Despite its effectiveness, it is suggested that`s impairs bone remodeling at the surgical site of spinal fusion, delaying the osteointegration of the bone graft to the vertebral bodies. There is still no consensus on the best approach for osteoporotic patients who are in chronic use of alendronate and who will undergo surgical procedure for spinal fusion. This study sought to examine the effect of the chronic use of alendronate on bone formation of spinal fusion in osteoporotic rats. Fifteen Sprague Dawley adult female rats were divided into three groups: Non-OVX (n=3) ­ non-ovariectomized rats submitted to posterolateral lumbar spinal fusion; OVX (n=5) - rats submitted to ovariectomy at 8 ­ 12 weeks of age and to posterolateral lumbar spinal fusion 12 weeks later; and ALN (n = 7) ­ ovariectomized rats submitted to spinal fusion in which weekly subcutaneous injections of Alendronate (70µg/kg) were administered from 5 weeks before the spinal fusion until euthanasia. Blood samples were collected weekly and euthanasia was performed 8 weeks after the spinal fusion procedure. Development of osteoporosis was evaluated through the plasmatic dosage of CTX-I, in which we observed a significant increase in the OVX group (p=0.0086). Bone loss was confirmed by micro-CT analysis of the fourth lumbar vertebra, with slightly reduction in the bone volume (BV/TV) (p=0.116), trabecular number (Tb.N) (p=0.116), significantly reduction in the trabecular tickness (Tb.Th) (p=0.033), and slightly increase in the trabecular bone pattern factor (TB.pf) (p = 0.086). Radiographic evaluation of the lumbar spine revealed fusion rate of 75% (3/4) in Non-OVX, 100% (3/3) in OVX, and no fusion in ALN. According to manual palpation, we observed similar results for the non-OVX and OVX goup, while in the ALN group we observed 57.1% (4/7) of fusion rate. New bone formation identified on µCT imaging of bilaterally fused specimens demonstrated a higher BV/TV (p ≤ 0.05), Tb.N (p ≤ 0.01), Tb.Sp (p ≤ 0.01), and connective density (Conn.Den, p = 0.02) in ALN than in nonOVX and OVX groups. The alendronate also improved the Tb.Th (p = 0.04) and Tb.pf (p = 0.03) in comparisson to OVX group. This study demonstrates that, despite the better quality of new bone formation after long term administration of alendronte in osteoporotic rats submitted to posterolateral spinal fusion, the treatment does not improve the fusion rates


Subject(s)
Osteoporosis , Spinal Fusion , Alendronate/therapeutic use
6.
Int. j. odontostomatol. (Print) ; 11(4): 481-485, dic. 2017. tab, graf
Article in Spanish | LILACS | ID: biblio-893292

ABSTRACT

RESUMEN: Los bisfosfonatos son potentes inhibidores de la resorción ósea. El aceite de oliva (O) presenta propiedades anti-inflamatorias y anti-oxidantes. Estudiar el efecto del tratamiento combinado de alendronato (AL) y pamidronato (PA) por vía subcutánea y de O vía oral sobre la regeneración tisular de cavidades óseas neoformadas.: 54 ratas macho de la línea Wistar, se dividieron en 6 grupos. Grupo control (C), recibieron solución salina vía subcutánea. Grupo (AL) recibió 0,5 mg de AL/Kg de peso corporal de por vía subcutánea. Grupo (PA) recibió de igual manera que el grupo anterior. Grupo (O) fue tratado con aceite de oliva con la dieta, 50 g/ Kg de comida. Grupo (ALO) recibió tratamiento combinado con AL y O. Grupo (PAO) recibió de igual tratamiento. Los sacrificios para la toma de muestras fueron a los 15, 30, 60 y 90 días. Para los estudios histopatológicos los cortes fueron teñidos con HE y observados con microscopía óptica. Los estudios estadísticos se realizaron a través del análisis de la variancia. A los quince días las áreas de los osteocitos del grupo PA se diferencian significativamente sólo respecto al grupo AL. En cuanto a la Densidad trabecular se observa un incremento de tejido óseo en todos los grupos. O mejora cualitativamente la estructura del hueso trabecular y cortical, preservando la mineralización, el tamaño y la estructura de los cristales minerales Esto sugiere que O representa una opción terapéutica prometedora para la prevención y tratamiento de las patologías óseas.


ABSTRACT: Bisphosphonates are potent inhibitors of bone resorption. Olive oil (O) has anti-inflammatory and anti-oxidant properties. To study the effect of combined treatment with alendronate (AL) and pamidronate (PA) subcutaneously or orally, and on tissue regeneration of newly formed bone cavities, we divided 54 male Wistar rats into 6 groups. Control group (C) received saline subcutaneously. Group (AL) received 0.5 mg of AL / kg body weight subcutaneously. Group (PA) received the same as the previous group. (O) was treated with olive oil diet, 50 g / kg of food. Group (ALO) received combined treatment with AL and O. Group (PAO) received the same treatment. The animals were euthanized for sampling at 15, 30, 60 and 90 days. For histopathology sections were stained with HE and observed these with light microscopy. Statistical studies were performed by analysis of variance. Fifteen days osteocytes areas of the PA group were significantly different only for the AL group. As the density increased trabecular bone tissue was observed in all groups. O qualitatively improved the structure of trabecular and cortical bone mineralization while preserving the size and structure of the mineral crystals. This suggests that O represents a promising therapeutic option for prevention and treatment of bone diseases.


Subject(s)
Animals , Male , Rats , Dental Implants , Peri-Implantitis , Rats, Wistar , Alendronate/administration & dosage , Alendronate/therapeutic use , Olive Oil/therapeutic use , Pamidronate/administration & dosage , Pamidronate/therapeutic use , Histology
7.
Rev. Asoc. Argent. Ortop. Traumatol ; 82(4): 327-333, dic. 2017. []
Article in Spanish | LILACS, BINACIS | ID: biblio-896277

ABSTRACT

Introducción: El objetivo de este estudio experimental fue evaluar el resultado radiológico e histológico del empleo de alendronato colocado localmente en el foco de fracturas de fémur en conejos. Materiales y Métodos: Se utilizaron 30 conejos a los cuales se les fracturó el fémur derecho y se los dividió en tres grupos de 10 animales cada uno. A los conejos del grupo 1 se les colocó una solución con alendronato en el foco de fractura; los del grupo 2 fueron sometidos al mismo procedimiento a los siete días de la fractura y el grupo 3 era de control. Se realizó la evaluación radiográfica en el momento de la fractura y a los 42 días del procedimiento. Se evaluaron las características del callo óseo mediante anatomía patológica, radiología y tomografía computarizada. Resultados: Se evaluaron 24 conejos (2 conejos del grupo 2 y 4 del grupo 3 murieron). El análisis histológico reveló moderada formación ósea en los tres grupos, sin diferencias estadísticamente significativas (p = 0,8336). Según los resultados de los estudios por imágenes, no existieron diferencias estadísticamente significativas en el tamaño del callo óseo entre los grupos para los dos estudios (radiografía: p = 0,777 y tomografía: p = 0,349). Conclusión: El alendronato colocado localmente en el foco de fractura, en la etapa aguda y luego de una semana, no alteró, de manera estadísticamente significativa, el proceso normal de consolidación, determinado por anatomía patológica y radiología, a las seis semanas de la fractura de fémur en conejos. Nivel de Evidencia: II


Introduction: The aim of this experimental study was to evaluate the radiologic and histological results of the use of alendronate administered locally at the fractures site in rabbits. Methods: The fractured right femur of 30 rabbits was used for evaluation. The animals were distributed in three groups of 10 rabbits each. A solution with alendronate was placed at the fracture site in group 1; the same procedure was performed 7 days after the fracture in group 2, and group 3 functioned as control. Radiographic evaluation was performed at the time of the fracture and at day 42. Radiological, PA and CT-scan evaluations of bone callus characteristics in each rabbit were performed. Results: Twenty-four rabbits were evaluated (2 rabbits in group 2 and 4 in group 3 died). Histological evaluation evidenced moderate bone formation in the three groups without statistically significant differences (p=0.8336). Concerning imaging studies, there were no statistically significant differences in the size of bone callus among groups for both studies (X-rays: p=0.777 and CT: p=0.349). Conclusion: The use of alendronate administered locally at the fracture site, in the acute period and after one week, did not alter the normal consolidation process determined by PA and radiology, six weeks after femur fracture in rabbits. Level of Evidence: II


Subject(s)
Animals , Fracture Healing/drug effects , Alendronate/therapeutic use , Disease Models, Animal , Fractures, Bone/pathology , Fractures, Bone/drug therapy , Femur/pathology , Rabbits
8.
Acta cir. bras ; 32(9): 781-795, Sept. 2017. graf
Article in English | LILACS | ID: biblio-886237

ABSTRACT

Abstract Purpose: To performed a histomorphometric and radiological study to evaluate the effects of alendronate sodium administered locally in mandibular bone defects created in rabbits. Methods: Two circular defects 5 mm in diameter were created bilaterally in the mandibular corpus of 20 New Zealand rabbits (i.e., four defects per animal). Each defect received one of four treatments: no treatment (EC group), alendronate irrigation (AL group), autogenous bone grafting (AG group), or alendronate irrigation with autogenous bone grafting (AL+AG group). Histomorphometric and radiological assessments were conducted at 4 and 8 weeks after surgery. Results: Between-group comparisons of the new bone area, the value of the AL+AG group was significantly lower thanthe remaining three groups at 4 weeks postoperatively. In all groups, the new bone area was significantly larger at 8 weeks than at 4 weeks. The residual graft area at 4 and 8 weeks was significantly higher in the AL+AG group than in the AG group, although it was significantly smaller at 8 weeks than at 4 weeks in both these groups. Conclusion: The use of alendronate sodium in conjunction with autogenous bone grafting improves the osteoconductive properties of the graft, enhances graft retention in the defect, and improves ossification.


Subject(s)
Animals , Male , Female , Rats , Bone Regeneration/drug effects , Fracture Healing/drug effects , Alendronate/therapeutic use , Fractures, Bone/drug therapy , Bone Density Conservation Agents/therapeutic use , Disease Models, Animal , Fractures, Bone/pathology , Fractures, Bone/diagnostic imaging
9.
ImplantNewsPerio ; 2(2): 301-308, mar.-abr. 2017.
Article in Portuguese | LILACS, BBO | ID: biblio-847154

ABSTRACT

O tratamento de defeitos ósseos intrabucais tem sido um desafi o na área odontológica, e a pesquisa de novas drogas para otimizar os resultados cirúrgicos regenerativos é de extrema importância. Existem evidências de que algumas drogas, como o ranelato de estrôncio (RSr), a sinvastatina (SNV) e o alendronato de sódio (ALE), têm propriedades anabólicas no metabolismo ósseo. A proposta desta revisão foi apresentar o estado atual da arte sobre o emprego da SNV, do RSr e do ALE em terapias odontológicas. Foi realizada uma busca bibliográfica na base PubMed e incluídos estudos relevantes relacionados ao tema para síntese deste trabalho. Concluiu-se que a aplicação do ALE e da SIN são efetivos como coadjuvantes no tratamento mêcanico da doença periodontal e como indutores de neoformação óssea, entretanto, o RSr merece ser mais bem estudado para tal afirmação.


The treatment of intraoral bone defects has been a challenge in dentistry, in this way the development of new drugs in order to optimize surgical regenerative results are extreme important. There are evidences that drugs such as strontium ranelate (RSr), simvastatin (SNV) and sodium alendronate (ALE) have anabolic properties in bone metabolism and several studies have been performed aiming to improve therapeutic strategies in bone regeneration. Therefore, the purpose of this review is to present the current state of art about the usage of SNV, RSr and ALE in dental therapies, targeting better clinical outcomes in bone manipulation techniques. A literature research was performed in PubMed database and relevant studies between were included. Our study concluded that application of ALE and SNV are effective as adjuncts with mechanical therapy of periodontal disease and also induces bone formation. In the other hand, the application of RSr as a promising bone formation drug needs to be better elucidated.


Subject(s)
Humans , Alendronate/therapeutic use , Bone Regeneration/drug effects , Periodontitis/drug therapy , Simvastatin/therapeutic use , Strontium/therapeutic use
10.
Arq. bras. med. vet. zootec. (Online) ; 68(2): 543-547, mar.-abr. 2016. ilus, graf
Article in English | LILACS, VETINDEX | ID: biblio-874956

ABSTRACT

O presente trabalho teve como objetivo avaliar a biocompatibilidade e a osseointegração de compósitos de hidroxiapatita (HA), policaprolactona (PCL) e alendronato (ALN) em defeitos ósseos produzidos no olécrano de coelhos. Trinta e seis coelhos foram distribuídos em quatro grupos, recebendo como tratamento: (1) compósito de HA (49,5%), PCL (49,5%) e ALN (1%); (2) HA (50%) e PCL (50%); (3) PCL (100%); e (4) solução salina 0,9%. As amostras para análise histológica foram coletadas de três animais de cada grupo aos oito, 45 e 90 dias de pós-operatório. No oitavo dia, as bordas do defeito ainda eram identificáveis em todos os grupos. Tecido ósseo novo era formado em contato com o biomaterial apenas nas formulações que incluíam HA. Essas características continuaram evidentes nos outros momentos analisados, embora o defeito estivesse preenchido pelo tecido regenerado. A presença dos biomateriais foi verificada nos três momentos em todos os grupos. Não houve evidências de reação indesejável ao biomaterial. As análises histológicas e histomorfométricas mostraram que os biomateriais são biocompatíveis e aqueles contendo a hidroxiapatita favoreceram a formação óssea no início do processo de regeneração, embora o alendronato não tenha apresentado qualquer efeito.(AU)


Subject(s)
Animals , Rabbits , Alendronate/therapeutic use , Biocompatible Materials/analysis , Biocompatible Materials/therapeutic use , Bone Regeneration , Hydroxyapatites/therapeutic use , Olecranon Process/abnormalities , Bone and Bones/anatomy & histology
12.
Belo Horizonte; s.n; 2014. 61 p. ilus, tab, graf.
Thesis in Portuguese | LILACS, BBO | ID: lil-790341

ABSTRACT

O alendronato de sódio é utilizado, na área médica, no tratamento da osteoporose e outras doenças ósseas. Nos últimos anos alguns estudos avaliaram o efeito do uso sistêmico do alendronato, principalmente, em defeitos ósseos decorrentes da evolução da doença periodontal inflamatória. Todavia, o uso sistêmico e prolongado do alendronato tem sido associado à osteonecrose dos maxilares. O objetivo deste ensaio clínico controlado randomizado foi avaliar o efeito do tratamento periodontal mecânico não cirúrgico, associado à aplicação tópica de alendronato de sódio a 1%, em indivíduos com periodontite. Para tanto, 16 indivíduos com periodontite crônica foram selecionados nas clínicas de Periodontia do Departamento de Odontologia da Pontifícia Universidade Católica de Minas Gerais, no período de abril de 2013 a maio de 2014...


Alendronate Sodium is medically used in the treatment of osteoporosis and other bone diseases. In the past few years, studies have evaluated the effect of systemic use of Alendronate Sodium, especially in the treatment of structural bone defects caused by the evolution of periodontal inflammatory diseases. However, the prolonged and systemic use of Alendronate Sodium has been associated with the treatment of osteonecrosis of the maxilla. The objective of this randomized and controlled clinical trial was to evaluate the effect of non-surgical mechanical periodontal treatment, associated with the topical application of Alendronate Sodium at 1%, to individuals presenting cases of periodontitis. To the case, 16 individuals presenting chronic periodontitis were selected in the periodontal clinics of the Odontology department from the Pontifícia Universidade Católica de Minas Gerais, in the period of April of 2013 to May of 2014. A complete periodontal exam was performed three and six months after the base exam, registeringthe following clinical parameters: probing depth, measured insertion loss, bleeding on probing, plaque index. The evaluation of the bone defects was performed using the technics of subtraction radiography and cone beam computerized tomography in the base exam and six months after the non-surgical ...(AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Alendronate/therapeutic use , Periodontal Diseases/therapy , Chronic Periodontitis/therapy , Placebos/therapeutic use , Bone Resorption , Diphosphonates , Subtraction Technique , Cone-Beam Computed Tomography
13.
Rev. Asoc. Argent. Ortop. Traumatol ; 79(4): 243-249, 2014. tab, ilus
Article in Spanish | LILACS | ID: lil-743076

ABSTRACT

Introducción: El propósito de este estudio experimental es investigar la variabilidad en la reabsorción ósea de aloinjertos impregnados con alendronato respecto a aloinjertos sin impregnación con alendronato. Materiales y Métodos: Se utilizaron 18 conejos neozelandeses, divididos en dos grupos de 9 animales cada uno. Se trabajó sobre el fémur derecho, se realizó una ventana ósea y se colocó aloinjerto con alendronato local en el grupo I y aloinjerto sin alendronato en el grupo II. Todos fueron sacrificados a las 10 semanas del procedimiento inicial, y se valoró el fémur operado con anatomía patológica, radiografías de frente y de perfil, y tomografía axial computarizada. Se evaluaron la osteointegración, la vascularización y la calidad ósea. Resultados: El estudio histológico demostró mayor osteointegración en el grupo I que en el grupo II (p = 0,003), y fenómenos bien definidos de “acoplamiento” entre el tejido óseo receptor e injertado, leve actividad osteoclástica. En el grupo II, se observó menor acoplamiento óseo (osteointegración). La evaluación de la reabsorción ósea con radiografía y tomografía computarizada no reveló una diferencia estadísticamente significativa entre ambos grupos. En el grupo I, se observó mayor osteointegración del aloinjerto (p = 0,577; no significativo). Conclusión: Los resultados obtenidos en este trabajo experimental muestran que el alendronato local asociado a aloinjertos ayuda a mejorar la osteointegración de los aloinjertos, que es un método seguro, y que no se asocia a riesgos locales o sistémicos en conejos, aun en dosis elevadas.


Background: The use of allografts in bone reconstruction may be associated with an increased absorption of the latter, which may cause loss of stability and failure of reconstructions. The purpose of this experimental study was to investigate the variability in bone resorption in alendronate impregnated allografts versus non-impregnated allografts. Methods: Eighteen New Zealand rabbits were divided into two groups of nine animals each. We worked on the right femur; a bone window was performed and allografts were placed (with alendronate in group I and without alendronate in group II). All rabbits were sacrificed at 10 weeks after the initial procedure. Femur was evaluated with pathology, frontal and lateral radiographs and computed tomography. Osteointegration, vascularization and bone quality were evaluated. Results: No deaths or infections were reported, with 18 rabbits up to final analysis. histology showed better osteointegration in group I than group II (p = 0.003), with well-defined attachment between receptor bone tissue and low osteoclastic activity. In group II, we observed less osteointegration. Assessment of bone resorption with radiographs and computed tomography showed no statistically significant difference between both groups. Group I showed more osteointegration of the allograft (p = 0.577; not significant). Conclusions: Results of this experimental study show that allografts impregnated with alendronate help to improve the osteointegration. Also, it is a safe way and it is not associated with local or systemic risks in rabbits, even with high doses of alendronate.


Subject(s)
Animals , Rabbits , Allografts , Alendronate/therapeutic use , Bone Resorption , Femur/surgery , Osseointegration , Femur/anatomy & histology , Femur/physiopathology , Femur/blood supply
14.
Araçatuba; s.n; 2014. 126 p. tab, ilus.
Thesis in Portuguese | LILACS, BBO | ID: biblio-870070

ABSTRACT

O objetivo deste estudo foi avaliar o reparo ósseo na interface osso/implante em ratas com osteoporose induzida. As ratas submetidas à ovariectomia bilateral foram alimentadas com uma dieta pobre em cálcio. Dois grupos receberam tratamento medicamentoso (raloxifeno [OVX RAL] ou alendronato [OVX ALE]) e outro grupo não recebeu nenhuma medicação (OVX ST). O grupo controle foi submetido à cirurgia fictícia e foi alimentado com uma dieta normal (SHAM DN). Cada animal recebeu um implante em cada tíbia. Os animais foram eutanasiados após 14 ou 42 dias. Foram realizadas as análises biomecânica (torque reverso), extensão linear de contato osso/implante (ELCOI) e dinâmica óssea periimplantar pela proporção dos fluorocromos calceína/alizarina, aplicando-se a análise de variância ANOVA e o pós-teste de Tukey (p<0,05). A imunoistoquímica marcou a precipitação de osteoprotegerina (OPG), RANKL, TRAP e osteocalcina (OC). O medicamento RAL melhorou o reparo ósseo periimplantar, em que o grupo ALE foi semelhante ao grupo OVX ST. Não houve diferenças estatisticamente significativas no torque reverso (p = 0,861), na precipitação dos fluorocromos (calceína/alizarina) e na ELCOI entre os grupos OVX RAL e grupo controle - SHAM DN (p > 0,05). As imunomarcações de OPG e RANKL foram similares para os grupos RAL e SHAM; houve moderada expressão de OC aos 14 dias. A TRAP foi marcada intensamente aos 42 dias para o grupo OVX. Portanto, o raloxifeno melhorou o reparo ósseo periimplantar de ratas osteoporóticas, sugerindo a sua indicação no tratamento da osteoporose.


The aim of this study was to evaluate the bone healing in bone/implant interface in rats with induced osteoporosis. The rats underwent bilateral ovariectomy were fed a diet low in calcium. Two groups received drug treatment (raloxifene [OVX RAL] or alendronate [OVX ALE]) and the other group received no medication (OVX NT). The control group underwent sham surgery and was fed a normal diet (SHAM ND). Each animal received an implant on the tibia. The animals were euthanized after 14 or 42 days. The biomechanical analysis (reverse torque), linear extension contact bone / implant (BIC) and bone dynamics periimplantar by the proportion of fluorochrome calcein/alizarin, applying the ANOVA and Tukey’s post-test (p<0.05). Immunohistochemistry marked precipitation of osteoprotegerin (OPG), RANKL, TRAP and osteocalcin (OC). The RAL improved drug peri-implant bone repair, wherein the ALE OVX group was similar to the ST group. There were no statistically significant differences in reverse torque (p = 0.861), precipitation of fluorochromes (calcein/alizarin) and BIC between OVX RAL and control groups - SHAM ND (p> 0.05). The immunostaining of OPG and RANKL were similar to RAL and SHAM groups; there was moderate OC expression at 14 days. TRAP was marked intensely at 42 days for the OVX group. Therefore, raloxifene improved peri-implant bone repair of osteoporotic rats, suggesting its indication in the treatment of osteoporosis.


Subject(s)
Animals , Rats , Alendronate/therapeutic use , Raloxifene Hydrochloride/therapeutic use , Bone Density Conservation Agents/therapeutic use , Dental Implants , Microscopy , Osteoporosis/chemically induced , Biomechanical Phenomena/physiology , Ovariectomy/rehabilitation , Rats, Wistar
15.
Article in Spanish | LILACS | ID: lil-687664

ABSTRACT

Objetivo: Determinar si existe relación entre tiempo de tratamiento con alendronato y necesidad de tratamiento periodontal en pacientes con osteoporosis posmenopáusica. Pacientes y Métodos: El estudio de corte transversal, descriptivo y observacional, incluyó un total de 112 pacientes con osteoporosis posmenopáusica atendidas en los Servicios de Gineco-Obstetricia o Reumatología del Hospital Belén de Trujillo, a las que se les realizó un examen clínico para determinar la necesidad de tratamiento periodontal y se registró el inicio de tratamiento con alendronato, según la historia clínica. Resultados: Se encontró relación significativa inversa entre tiempo de tratamiento con alendronato y necesidad de tratamiento periodontal en pacientes con osteoporosis posmenopáusica (p<0.05 y r=-0.533). Además, el 84.1 por ciento de pacientes presentó más de 6 meses de consumo de alendronato y el código 2 del Índice de Necesidad de Tratamiento Periodontal en la Comunidad fue el más frecuente para esta población. Conclusión: Los resultados permiten concluir que existe relación inversa entre tiempo de tratamiento con alendronato y necesidad de tratamiento periodontal en pacientes con osteoporosis posmenopáusica. Recomendación: Se recomienda realizar investigaciones sobre la utilidad que podría tener el alendronato como coadyuvante en el tratamiento de la enfermedad periodontal en mujeres con osteoporosis posmenopáusica.


Objective: To determine the correlation between the duration of alendronate’s treatment and the need for periodontal treatment in patients with postmenopausal osteoporosis. Patients and Methods: This cross-sectional, descriptive and observational study included a total of 112 patients with postmenopausal osteoporosis treated in Gyneco-Obstetric or Rheumatology Services at Hospital Belén de Trujillo, who underwent a clinical examination to determine the need for periodontal treatment. The start of the treatment with alendronate was registered, according to medical records. Results: We found significant inverse relationship between treatment duration with alendronate and periodontal treatment need in patients with postmenopausal osteoporosis (p<0.05 and r=-0.533). In addition, 84.1 percent of patients had more than 6 months of alendronate consumption and code 2 Community Periodontal Index of Need for Periodontal Treatment was the most frequent in this population. Conclusion: The results suggest that there is an inverse relationship between treatment duration with alendronate and periodontal treatment needs in patients with postmenopausal osteoporosis. Recommendation: it is suggested to carry out research about the utility that alendronate could have as an adjunct in the treatment of periodontal disease in women with postmenopausal osteoporosis.


Subject(s)
Humans , Female , Middle Aged , Alendronate/therapeutic use , Periodontal Diseases/drug therapy , Needs Assessment , Osteoporosis, Postmenopausal , Age Factors , Cross-Sectional Studies , Bone Density Conservation Agents/therapeutic use , Epidemiology, Descriptive , Health Services Needs and Demand , Postmenopause , Time Factors
16.
Braz. oral res ; 27(3): 252-257, May-Jun/2013. tab, graf
Article in English | LILACS | ID: lil-673245

ABSTRACT

Precise techniques for the measurement of maxillary bone mineral density (BMD) are useful for the early diagnosis of systemic diseases. The aim of this study was to compare in vivo the efficacy of dual-energy x-ray absorptiometry (DXA) and radiographic densitometry for the measurement of BMD after systemic administration of sodium alendronate. Wistar rats were randomly allocated to a control group (n = 5), which received distilled water, and a sodium alendronate group (n = 8), which received two doses of chemically pure sodium alendronate (1 mg/kg) per week. After 8 weeks, the animals were euthanized, the tibias were removed, and the BMD of the proximal tibial metaphysis was analyzed radiographically and by DXA. The data were subjected to statistical analysis by the Kruskal-Wallis test at a significance level of 5%. Both of the techniques revealed that the alendronate-treated group had a significantly higher BMD (p < 0.05) than the control group after 8 weeks of treatment. Comparing the groups with and without alendronate therapy revealed increases of 14.9% and 29.6% in BMD, as detected radiographically and by DXA, respectively. In conclusion, both of the methods were able to detect an increase in BMD of the proximal tibial metaphysis after alendronate therapy.


Subject(s)
Animals , Male , Rats , Alendronate/therapeutic use , Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Densitometry/methods , Absorptiometry, Photon/methods , Osteoporosis , Random Allocation , Rats, Wistar , Reproducibility of Results , Tibia
17.
Rev. saúde pública ; 47(2): 390-402, jun. 2013. tab
Article in Portuguese | LILACS | ID: lil-685567

ABSTRACT

OBJETIVO: Analisar os gastos com medicamentos para o tratamento da osteoporose na pós-menopausa e os fatores associados ao gasto médio per capita . MÉTODOS: Pareamento probabilístico-determinístico a partir das bases das Autorizações de Procedimentos de Alta Complexidade com o Sistema de Informação sobre Mortalidade, resultando em coorte histórica de pacientes que utilizaram medicamentos de alto custo para o tratamento da osteoporose na pós-menopausa de 2000 a 2006. O gasto médio mensal com medicamentos foi estratificado por faixas etárias e descrito de acordo com as características demográficas, clínicas e tipo de medicamento utilizado. Foi utilizado modelo de regressão linear para avaliar o impacto de características demográficas e clínicas sobre o gasto médio mensal per capita com os medicamentos. RESULTADOS: Foram identificadas 72.265 mulheres que receberam medicamentos para o tratamento da osteoporose na pós-menopausa. O gasto médio mensal per capita no primeiro ano de tratamento foi de R$ 90,00 (dp R$ 144,49). A maioria das mulheres tinha de 60 a 69 anos de idade, iniciaram tratamento em 2000, eram residentes na região Sudeste, tinham fraturas osteoporóticas prévias e o alendronato de sódio foi o medicamento mais utilizado no início do tratamento. A maioria das pacientes permaneceu em uso do mesmo princípio ativo durante o tratamento. Foram identificados 6.429 óbitos entre as participantes. Mais de um terço das mulheres permaneceram no programa por até 12 meses. Raloxifeno e calcitonina sintética foram as alternativas com maior impacto sobre o gasto médio mensal com medicamentos, tendo como padrão de referência o ...


OBJECTIVE: To analyze expenditure on treatment for postmenopausal osteoporosis and associated factors on mean per capita expenditure. METHODS: A probabilistic-deterministic linkage between the database of Authorizations for Highly Complex Procedures and the mortality information system was constructed, resulting in a historical cohort of patients using high-cost medications for the treatment of postmenopausal osteoporosis, between 2000-2006. Mean monthly spending on medicines was stratified by age group and described according to demographic and clinical characteristics and the type of drug used. A linear regression model was used to assess the impact of demographic and clinical characteristics on per capita mean monthly expenditure on medicines. RESULTS: We identified 72,265 women who received drugs for the treatment of postmenopausal osteoporosis. The average monthly expenditure per capita in the first year of treatment was $ 54.02 (sd $ 86.72). The population was predominantly composed of women aged 60-69 years old, who had started treatment in 2000, resident in the Southeast of Brazil, who had previously suffered osteoporotic fractures, and Alendronate sodium was the drug most commonly used at baseline. For most of the patients, the same active ingredient remained in use throughout the treatment period. During the program, 6,429 deaths were identified among participants. More than a third of women remained in treatment for up to 12 months. Raloxifen and calcitonin were the therapeutic alternatives with the greatest impact on the average monthly expenditure on medicine using alendronate sodium as a reference standard. CONCLUSIONS: Due to the high impact of the type of drug used on expenditure on medication, it is recommended that criteria for prescribing and dispensing ...


OBJETIVO: Analizar los gastos con medicamentos para el tratamiento de la osteoporosis en la post-menopausia y los factores asociados al gasto promedio per cápita. MÉTODOS: Pareamiento probabilístico-deterministico a partir de las bases de las Autorizaciones de Procedimientos de Alta Complejidad con el Sistema de Información sobre Mortalidad, resultando en cohorte histórica de pacientes que utilizaron medicamentos de alto costo para el tratamiento de la osteoporosis en la post-menopausia de 2000 a 2006. El gasto promedio mensual con medicamentos fue estratificado por grupos etarios y descrito de acuerdo con las características demográficas, clínicas y tipo de medicamento usado. Se utilizó modelo de regresión linear para evaluar el impacto de las características socio demográficas y clínicas sobre el gasto promedio mensual per cápita con los medicamentos. RESULTADOS: Se identificaron 72.265 mujeres que recibieron medicamentos para el tratamiento de la osteoporosis en la post-menopausia. El gasto promedio mensual per cápita en el primer año de tratamiento fue de R$ 90,00 (de R$ 144,49). La mayoría de las mujeres tenía de 60 a 69 años de edad, iniciaron tratamiento en 2000, eran residentes en la región Sureste, tenían fracturas osteoporóticas previas, y el alendronato de sodio fue el medicamento más utilizado en el inicio del tratamiento. La mayoría de los pacientes permaneció en uso del mismo principio activo durante el tratamiento. Se identificaron 6.429 óbitos entre las participantes. Más de un tercio de las mujeres permanecieron en el programa por 12 meses. Raloxifeno y calcitonina sintética fueron las alternativas con mayor impacto sobre el gasto promedio mensual con medicamentos, teniendo como patrón de referencia ...


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Bone Density Conservation Agents/economics , Drug Costs , Osteoporosis, Postmenopausal/drug therapy , Age Factors , Alendronate/economics , Alendronate/therapeutic use , Bone Density , Bone Density Conservation Agents/therapeutic use , Brazil/epidemiology , Cohort Studies , Cost-Benefit Analysis , National Health Programs , Osteoporosis, Postmenopausal/epidemiology , Osteoporotic Fractures/epidemiology , Unified Health System
18.
São Paulo; s.n; 2013. 74 p. ilus, tab. (BR).
Thesis in Portuguese | LILACS, BBO | ID: lil-713913

ABSTRACT

Os bisfosfonatos são drogas capazes de inibir a reabsorção óssea por meio de seu efeito direto sobre as células ósseas, interferindo na dinâmica dos tecidos mineralizados. O alendronato (ALN), um tipo de bisfosfonato nitrogenado, foi utilizado com o objetivo de investigar os seus efeitos sobre os tecidos dentários e periodontais após luxação lateral de molares com as raízes em desenvolvimento. Ratos Wistar com 21 dias de idade tiveram os segundos molares superiores luxados lateralmente. Doses diárias de 2,5 mg / kg de ALN começaram no dia seguinte à luxação; os controles receberam solução salina estéril. As maxilas foram fixadas, descalcificadas e incluídas em parafina ou em resina Spurr 7, 14 e 21 dias pós-luxação. Os cortes foram corados com H & E, incubados por histoquímica TRAP e imuno marcados para osteopontina (OPN), bem como para análise ultraestrutural. Após 21 dias, o ápice dos molares luxados sem ALN estava aberto e desorganizado, coberto por uma camada irregular de cemento celular. Os molares luxados dos animais tratados com ALN apresentaram alguns locais de anquilose, bem como lacunas de reabsorção na superfície do cemento. Os osteoclastos TRAP positivos foram mais numerosos no grupo ALN, apesar de sua aparência latente e sua localização, afastados das trabéculas ósseas, em relação aos controles, achado que foi confirmado com a análise ultraestrutural. A imunomarcação de OPN revelou uma linha grossa imunopositiva na dentina, que deve ter surgido a partir do momento da luxação, enquanto que as amostras tratadas com ALN não apresentaram alterações na dentina. Os resultados indicam que o alendronato inibe algumas alterações na dentina e na formação do cemento, induzidas pelo trauma dental de luxação.


Bisphosphonates are drugs that inhibit bone resorption through its direct effect on bone cells, interfering with the dynamics of mineralized tissues. Alendronate (ALN), a nitrogenated bisphosphonate, was used in order to investigate their effects on dental and periodontal tissues after lateral dislocation of molars with developing roots. Twenty one days old Wistar rats had their second molars laterally l. Daily doses of 2.5 mg / kg ALN started the day following the dislocation, while controls received saline solution. The maxillae were fixed, decalcified and embedded in paraffin or in Spurr resin after 7, 14 and 21 days post-dislocation. The sections were stained with H & E, incubated for TRAP, immunolabeled for osteopontin (OPN), and ultrastructurally analyzed by transmission electron microscopy. After 21 days, the apex of the luxated molar without ALN was open and disorganized, covered by an irregular layer of cellular cementum. The luxated molar from ALN-treated animals showed some areas of ankylosis and resorption lacunae on the cementum surface. TRAP-positive osteoclasts were more numerous in the ALN group, despite their latent appearance compared to controls, a finding that was ultrastructurally confirmed. OPN immunostaining revealed a thick immunopositive line in dentin, which must be resultant from the moment of dislocation, while the samples treated with ALN showed no changes in dentin. The results indicate that alendronate inhibits some changes in dentin and cementum formation induced by dental trauma of lateral luxation.


Subject(s)
Animals , Rats , Alendronate/therapeutic use , Tooth Avulsion/diagnosis , Diphosphonates/pharmacology , Osteoclasts/physiology , Bone Resorption/diagnosis
19.
Braz. j. otorhinolaryngol. (Impr.) ; 78(2): 73-79, mar.-abr. 2012. tab
Article in Portuguese | LILACS | ID: lil-622846

ABSTRACT

A otospongiose é uma osteodistrofia focal primária da cápsula ótica que acomete indivíduos geneticamente predispostos e promove perda auditiva progressiva. OBJETIVO: Verificar a aplicabilidade da avaliação audiométrica no tratamento medicamentoso da otospongiose. MATERIAL E MÉTODO: Estudo prospectivo, randomizado, controlado, duplo-cego, envolvendo 26 pacientes com diagnóstico clínico, audiométrico e tomográfico de otospongiose. Os pacientes elegíveis para o estudo foram alocados em três grupos (A, B e C) e receberam o tratamento com alendronato de sódio (B), fluoreto de sódio (C) e placebo (A) por 6 meses. Após este período, os mesmos realizaram nova avaliação audiométrica. RESULTADOS: Na análise das diferenças entre as vias aérea e óssea (gap), não houve diferença estatisticamente significante. Também não foram encontradas diferenças em relação ao limiar de reconhecimento da fala (SRT) e a discriminação vocal (IRF) entre os períodos pré e pós-tratamento. CONCLUSÃO: Após seis meses de tratamento medicamentoso, a avaliação audiométrica evidenciou manutenção dos limiares auditivos, sugerindo estabilização da atividade da lesão otospongiótica.


Otospongiosis is a primary osteodystrophy of the otic capsule that affects genetically predisposed individuals and leads to a progressive hearing loss. AIM: To evaluate the applicability of audiometric evaluation during drug treatment for otospongiosis. MATERIALS AND METHODS: A prospective, randomized, controlled, double-blind study involving 26 patients with clinical, audiometric and CT scan image of otosclerosis. Patients eligible for the study were divided into three groups (A, B and C) and received treatment with alendronate sodium (B), sodium fluoride (C) and placebo (A) for 6 months. After this period they were submitted to new tests. RESULTS: There were not statistically significant differences between air and bone conduction (gap). We also found no differences in the speech recognition threshold (SRT) and speech discrimination (IRF) between before and after treatment. CONCLUSION: After six months of drug treatment the audiometric evaluation kept the same hearing thresholds, suggesting stabilization of the otospongiotic lesions.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Audiometry , Alendronate/therapeutic use , Bone Density Conservation Agents/therapeutic use , Otosclerosis/drug therapy , Sodium Fluoride/therapeutic use , Auditory Threshold , Bone Conduction , Case-Control Studies , Double-Blind Method , Hearing Loss/drug therapy , Prospective Studies
20.
An. bras. dermatol ; 87(1): 155-156, Jan.-Feb. 2012. ilus
Article in English | LILACS | ID: lil-622471

ABSTRACT

The SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) includes a group of findings characterized by bone lesions usually located on the anterior chest wall, often associated with skin lesions. We report the case of a 47 years old patient, with osteochondritis at costoesternal and manubrium-sternal joints, besides of palmar-plantar pustulosis. The diagnosis is predominantly clinical and there are several treatment options described in the literature.


A síndrome SAPHO (sinovite, acne, pustulose, hiperostose e osteíte) inclui um grupo de achados caracterizado por lesões ósseas localizadas geralmente na parede torácica anterior, frequentemente associadas a lesões cutâneas. Relata-se o caso de uma paciente de 47 anos, com quadro clínico composto por osteocondrite de articulação costoesternal e manúbrio-esternal, além de pustulose palmo-plantar. O diagnóstico é predominantemente clínico e há diversas opções de tratamento descritas na literatura.


Subject(s)
Female , Humans , Middle Aged , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/drug therapy , Alendronate/therapeutic use , Dermatologic Agents/therapeutic use , Methotrexate/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL